Skip to content

Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01904799
Acronym
Casper
Enrollment
263
Registered
2013-07-22
Start date
2015-01-02
Completion date
2019-03-29
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions. The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions. Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language. The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) : * for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions); * the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.

Interventions

OTHERCognitive Assessment test

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For CVA patients * patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ; * aged \> 18; * absence of severe disorders of oral comprehension (BDAE aphasia severity score \>2 for comprehension); * whatever the severity of oral expression disorders; * who have been given clear written and oral information, and after the doctor has verified their ability to understand the protocol. For " Control " patients (to evaluate divergent validity) * patients hospitalised in rehabilitation units or geriatrics taking part in this study; * aged \> 18.

Exclusion criteria

For CVA patients * patients who do not speak French; * cognitive disorders known before the CVA; * psychotic disorders known before the CVA; * major visual disorders incompatible with reading, known before the CVA. For " Control " patients (to evaluate divergent validity) * patients who do not speak French; * cognitive disorders known before the CVA; * psychotic disorders known before the CVA; * major visual disorders incompatible with reading, known before the CVA.

Design outcomes

Primary

MeasureTime frame
comprehensive assessment battery of higher functionsbaseline
test of visual memorybaseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026